Skip to content

Study · Randomized controlled trial · n = 4,597 · 2016

8 results

EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.

O'Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora P, Ortiz RV, Guerrero G, Claudius B, Pi-Sunyer X

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2 Aug 2016Cited by 18 (Europe PMC)

PMID27482610 (opens in a new tab)DOI10.4158/ep151181.or (opens in a new tab)PepBankPUB-27482610
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In non-Hispanic adults with overweight or obesity, liraglutide 3.0 mg gave greater mean weight loss than placebo at end of treatment.

    In plain wordsIn non-Hispanic adults with overweight or obesity, liraglutide led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean weight loss in non-Hispanic subgroup
    Study

    n = 4,597

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Weight loss
    7.5%
    non-Hispanics liraglutide 3.0 mg
    Weight loss
    2.3%
    non-Hispanics placebo
    Treatment difference
    −5.2%
    non-Hispanics

    Source sentences

    Summary
    Both subgroups achieved clinically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg versus placebo: Hispanics 7.0% versus 1.5%, treatment difference -5.1% (95% CI, -6.2 to -4.0); non-Hispanics 7.5% versus 2.3%, -5.2% (95% CI, -5.5 to -4.8).
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Hispanic adults with overweight or obesity, liraglutide 3.0 mg gave greater mean weight loss than placebo at end of treatment.

    In plain wordsIn Hispanic adults with overweight or obesity, liraglutide led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean weight loss in Hispanic subgroup
    Study

    n = 534

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Weight loss
    7%
    Hispanics liraglutide 3.0 mg
    Weight loss
    1.5%
    Hispanics placebo
    Treatment difference
    −5.1%
    Hispanics

    Source sentences

    Summary
    Both subgroups achieved clinically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg versus placebo: Hispanics 7.0% versus 1.5%, treatment difference -5.1% (95% CI, -6.2 to -4.0); non-Hispanics 7.5% versus 2.3%, -5.2% (95% CI, -5.5 to -4.8).
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Hispanic and non-Hispanic adults with overweight or obesity, more individuals lost at least 5% of baseline weight with liraglutide 3.0 mg than with placebo.

    In plain wordsIn adults with overweight or obesity, more people lost at least 5% of their weight with liraglutide than with placebo, in both subgroups.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion losing at least 5% of baseline weight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    More individuals in both subgroups lost ≥5%, >10%, and >15% of their baseline weight with liraglutide 3.0 mg than with placebo.
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Hispanic and non-Hispanic adults with overweight or obesity, more individuals lost more than 10% of baseline weight with liraglutide 3.0 mg than with placebo.

    In plain wordsIn adults with overweight or obesity, more people lost over 10% of their weight with liraglutide than with placebo, in both subgroups.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion losing more than 10% of baseline weight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    More individuals in both subgroups lost ≥5%, >10%, and >15% of their baseline weight with liraglutide 3.0 mg than with placebo.
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Hispanic and non-Hispanic adults with overweight or obesity, more individuals lost more than 15% of baseline weight with liraglutide 3.0 mg than with placebo.

    In plain wordsIn adults with overweight or obesity, more people lost over 15% of their weight with liraglutide than with placebo, in both subgroups.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion losing more than 15% of baseline weight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    More individuals in both subgroups lost ≥5%, >10%, and >15% of their baseline weight with liraglutide 3.0 mg than with placebo.
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.
  6. 06HumanRandomized controlled trialEfficacy outcome

    Efficacy endpoints of liraglutide 3.0 mg versus placebo generally did not differ between Hispanic and non-Hispanic subgroups.

    In plain wordsLiraglutide's effects did not generally differ between Hispanic and non-Hispanic adults.

    Peptide
    Liraglutide
    Outcome
    No significant changeDifference in efficacy endpoints by ethnicity
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Efficacy endpoints generally did not vary with ethnicity (P>.05).
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.
  7. 07HumanRandomized controlled trialSafety outcome

    Adverse events with liraglutide 3.0 mg were comparable between Hispanic and non-Hispanic subgroups.

    In plain wordsSide effects with liraglutide were similar in Hispanic and non-Hispanic adults.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdverse events by ethnic subgroup
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Adverse events were comparable between ethnic subgroups
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.
  8. 08HumanRandomized controlled trialSafety outcome

    More gastrointestinal disorders were reported with liraglutide 3.0 mg than with placebo.

    In plain wordsStomach and bowel problems were reported more often with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal disorders
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    more gastrointestinal disorders reported with liraglutide 3.0 mg than placebo.
    2 context sentences
    Summary · context
    This post hoc analysis of pooled data from 4 phase 3a trials compared the efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to a reduced-calorie diet and physical activity, in Hispanic versus non-Hispanic subgroups.
    Summary · context
    We conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 4 completed · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01557166

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Novo Nordisk A/Sn = 3597 Jun 2012 to 17 Jun 2013

Metabolism and Nutrition Disorder · Obesity · Obstructive Sleep Apnoea

Trial pageClinicalTrials.govUpdated 1 Nov 2017
CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 19 Jan 2018
CompletedPhase 3Results postedNCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Novo Nordisk A/Sn = 8461 Jun 2011 to 25 Jan 2013

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 29 Dec 2017
CompletedPhase 3Results postedNCT00781937

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Novo Nordisk A/Sn = 42230 Oct 2008 to 1 Sept 2010

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 1 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.